Noah Peyser

Dr. Noah Peyser

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2023 in Nature
Verified
Journal Article
Open access
PDF file
DADanillo G Augusto
Danillo G Augusto
LMLawton D. Murdolo
Lawton D. Murdolo
DCDemetra S. M. Chatzileontiadou
Demetra S. M. Chatzileontiadou
JSJoseph J. Sabatino
Joseph J. Sabatino
TYTasneem Yusufali
Tasneem Yusufali
JHJill A. Hollenbach
Jill A. Hollenbach
Studies have demonstrated that at least 20% of individuals infected with SARS-CoV-2 remain asymptomatic1–4. Although most global efforts have focused on severe illness in COVID-19, examining asymptomatic infection provides a unique opportunity to consider early immunological features that promote rapid viral clearance. Here, postulating that variation in the human leukocyte antigen (HLA) loci may underly processes mediating asymptomatic infection, we enrolled 29,947 individuals, for whom high-resolution HLA genotyping data were available, in a smartphone-based study designed to track COVID-19 symptoms and outcomes. Our discovery cohort (n = 1,428) comprised unvaccinated individuals who reported a positive test result for SARS-CoV-2. We tested for association of five HLA loci with disease course and identified a strong association between HLA-B*15:01 and asymptomatic infection, observed in two independent cohorts. Suggesting that this genetic association is due to pre-existing T cell immunity, we show that T cells from pre-pandemic samples from individuals carrying HLA-B*15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF. The majority of the reactive T cells displayed a memory phenotype, were highly polyfunctional and were cross-reactive to a peptide derived from seasonal coronaviruses. The crystal structure of HLA-B*15:01–peptide complexes demonstrates that the peptides NQKLIANQF and NQKLIANAF (from OC43-CoV and HKU1-CoV) share a similar ability to be stabilized and presented by HLA-B*15:01. Finally, we show that the structural similarity of the peptides underpins T cell cross-reactivity of high-affinity public T cell receptors, providing the molecular basis for HLA-B*15:01-mediated pre-existing immunity.

30 August 2021 in JMIR Research Protocols
Verified
Journal Article
Open access
ABAlexis L Beatty
Alexis L Beatty
NPNoah Peyser
Noah Peyser
XBXochitl E Butcher
Xochitl E Butcher
TCThomas W Carton
Thomas W Carton
JOJeffrey E Olgin
Jeffrey E Olgin
GMGregory M Marcus
Gregory M Marcus
Background: The COVID-19 pandemic has catalyzed a global public response and innovation in clinical study methods. Objective: The COVID-19 Citizen Science study was designed to generate knowledge about participant-reported COVID-19 symptoms, behaviors, and disease occurrence. Methods: COVID-19 Citizen Science is a longitudinal cohort study launched on March 26, 2020, on the Eureka Research Platform. This study illustrates important advances in digital clinical studies, including entirely digital study participation, targeted recruitment strategies, electronic consent, recurrent and time-updated assessments, integration with smartphone-based measurements, analytics for recruitment and engagement, connection with partner studies, novel engagement strategies such as participant-proposed questions, and feedback in the form of real-time results to participants. Results: As of February 2021, the study has enrolled over 50,000 participants. Study enrollment and participation are ongoing. Over the lifetime of the study, an average of 59% of participants have completed at least one survey in the past 4 weeks. Conclusions: Insights about COVID-19 symptoms, behaviors, and disease occurrence can be drawn through digital clinical studies. Continued innovation in digital clinical study methods represents the future of clinical research. International Registered Report Identifier (IRRID): DERR1-10.2196/28169

17 February 2022 in Contemporary Clinical Trials
Verified
Journal Article
Open access
NPNoah Peyser
Noah Peyser
GMGregory M. Marcus
Gregory M. Marcus
ABAlexis L. Beatty
Alexis L. Beatty
JOJeffrey E. Olgin
Jeffrey E. Olgin
MPMark J. Pletcher
Mark J. Pletcher
Clinical trials are critically necessary for evaluating new medical drugs, devices, and other interventions designed to improve health. Digital methods have the potential to dramatically reduce the time and expense involved in clinical research, though they also pose new challenges for investigators. The Eureka Research Platform was developed as a national resource for digitizing and mobilizing health research. Platforms like Eureka enable innovation in trial design and methods, enabling remote recruitment strategies, mobile health data collection through connected devices and apps, geofencing for event ascertainment and location-based data collection, ecological momentary assessments, and intervention delivery. Here we describe our cumulative Eureka experience across more than 50 studies launched to date and offer perspectives on emerging opportunities.

13 September 2023 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NNNhung Nguyen
Nhung Nguyen
NPNoah Peyser
Noah Peyser
JOJeffrey E. Olgin
Jeffrey E. Olgin
MPMark J. Pletcher
Mark J. Pletcher
ABAlexis L. Beatty
Alexis L. Beatty
GMGregory M. Marcus
Gregory M. Marcus
Background: Little is known about whether people who use both tobacco and cannabis (co-use) are more or less likely to have mental health disorders than single substance users or non-users. We aimed to examine associations between use of tobacco and/or cannabis with anxiety and depression. Methods: We analyzed data from the COVID-19 Citizen Science Study, a digital cohort study, collected via online surveys during 2020–2022 from a convenience sample of 53,843 US adults (≥ 18 years old) nationwide. Past 30-day use of tobacco and cannabis was self-reported at baseline and categorized into four exclusive patterns: tobacco-only use, cannabis-only use, co-use of both substances, and non-use. Anxiety and depression were repeatedly measured in monthly surveys. To account for multiple assessments of mental health outcomes within a participant, we used Generalized Estimating Equations to examine associations between the patterns of tobacco and cannabis use with each outcome. Results: In the total sample (mean age 51.0 years old, 67.9% female), 4.9% reported tobacco-only use, 6.9% cannabis-only use, 1.6% co-use, and 86.6% non-use. Proportions of reporting anxiety and depression were highest for the co-use group (26.5% and 28.3%, respectively) and lowest for the non-use group (10.6% and 11.2%, respectively). Compared to non-use, the adjusted odds of mental health disorders were highest for co-use (Anxiety: OR = 1.89, 95%CI = 1.64–2.18; Depression: OR = 1.77, 95%CI = 1.46–2.16), followed by cannabis-only use, and tobacco-only use. Compared to tobacco-only use, co-use (OR = 1.35, 95%CI = 1.08–1.69) and cannabis-only use (OR = 1.17, 95%CI = 1.00–1.37) were associated with higher adjusted odds for anxiety, but not for depression. Daily use (vs. non-daily use) of cigarettes, e-cigarettes, and cannabis were associated with higher adjusted odds for anxiety and depression. Conclusions: Use of tobacco and/or cannabis, particularly co-use of both substances, were associated with poor mental health. Integrating mental health support with tobacco and cannabis cessation may address this co-morbidity.

21 September 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
ALAnthony Lin
Anthony Lin
EVEric Vittinghoff
Eric Vittinghoff
JOJeffrey Olgin
Jeffrey Olgin
NPNoah Peyser
Noah Peyser
SASidney Aung
Sidney Aung
GMGregory M Marcus
Gregory M Marcus
Objective Until effective treatments and vaccines are made readily and widely available, preventative behavioural health measures will be central to the SARS-CoV-2 public health response. While current recommendations are grounded in general infectious disease prevention practices, it is still not entirely understood which particular behaviours or exposures meaningfully affect one’s own risk of incident SARS-CoV-2 infection. Our objective is to identify individual-level factors associated with one’s personal risk of contracting SARS-CoV-2. Design Prospective cohort study of adult participants from 26 March 2020 to 8 October 2020. Setting The COVID-19 Citizen Science Study, an international, community and mobile-based study collecting daily, weekly and monthly surveys in a prospective and time-updated manner. Participants All adult participants over the age of 18 years were eligible for enrolment. Primary outcome measure The primary outcome was incident SARS-CoV-2 infection confirmed via PCR or antigen testing. Results 28 575 unique participants contributed 2 479 149 participant-days of data across 99 different countries. Of these participants without a history of SARS-CoV-2 infection at the time of enrolment, 112 developed an incident infection. Pooled logistic regression models showed that increased age was associated with lower risk (OR 0.98 per year, 95% CI 0.97 to 1.00, p=0.019), whereas increased number of non-household contacts (OR 1.10 per 10 contacts, 95% CI 1.01 to 1.20, p=0.024), attending events of at least 10 people (OR 1.26 per 10 events, 95% CI 1.07 to 1.50, p=0.007) and restaurant visits (OR 1.95 per 10 visits, 95% CI 1.42 to 2.68, p<0.001) were associated with significantly higher risk of incident SARS-CoV-2 infection. Conclusions Our study identified three modifiable health behaviours, namely the number of non-household contacts, attending large gatherings and restaurant visits, which may meaningfully influence individual-level risk of contracting SARS-CoV-2.

1 March 2021 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
SASidney Aung
Sidney Aung
EVEric Vittinghoff
Eric Vittinghoff
GNGregory Nah
Gregory Nah
NPNoah Peyser
Noah Peyser
MPMark J Pletcher
Mark J Pletcher
GMGregory M Marcus
Gregory M Marcus
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (Covid-19), has been a serious threat to global health. Previous work has focused primarily on hospitalized patients or on identifying risk factors for disease severity and mortality once the infection has taken place. We sought to leverage the ubiquity of smartphones and mobile applications to study risk factors for Covid-19 infection in a large, geographically heterogenous cohort. Methods: We analyzed data obtained from the Covid-19 Citizen Science (CCS) Study, a worldwide, mobile application-based cohort. After employing forward selection to identify variables with p values < 0.1, multivariable logistic regression models were utilized to identify independent risk factors associated with prevalent SARS-CoV-2 infection. Results: Among 36,041 participants in 113 countries and all 50 states in the US, 484 participants had prevalent SARS-CoV-2 infection. After multivariable adjustment, being a healthcare worker, living with at least one school-aged child, having pets at home, and having immunodeficiency were each associated with an increased odds of SARS-CoV-2. The association between pets and prevalent SARS-CoV-2 was driven by dog ownership. After adjustment for the same covariates, Asian or Pacific Islander race, receiving a flu shot within the past year, increased level of education, and smoking or vaping marijuana within the last 30 days were each associated with a lower odds of SARS-CoV-2. Conclusion: We identified various characteristics and behaviors, many of which are potentially modifiable, associated with prevalent SARS-CoV-2 infection in a world-wide mobile application-based cohort.